Form D · Biotechnology

Imbria Pharmaceuticals, Inc.

Boston, MA · CIK 0001745672

Offering snapshot reported Dec 16, 2025 · SEC filing

Reported sold
$66.7M
Offering amount: $144M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 10, 2025
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$33.3M$66.7MApr 1, 2025: $59,195,818.00Apr 1, 2025Dec 16, 2025: $66,695,817.00Dec 16, 2025

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$59,195,818 → $66,695,817
  • Reported investors8 → 10

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 16, 2025Amendment$66,695,817$7,499,999vs Apr 1, 202510SEC filing
Apr 1, 2025Initial$59,195,818No comparison8SEC filing
Jul 2, 2020Initial$40,734,932No comparison4SEC filing
Jul 9, 2018Initial$40,249,995No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-542691

Source: Form D, filed Dec 16, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Zina Affas Besse Director
Pieter Boelhouwer Director
Pavan Cheruvu Director
Charles Dunn Director
David Alexandre C. Gros Executive
Ken Horne Director
James Januzzi Director
Komal Joshi Executive
Andrew Levin Director
Rebecca Luse Director
Luse Rebecca Director
Alvin Shih Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
265 Franklin Street Suite #1702
Boston, MA, 02110